Online inquiry

IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10126MR)

This product GTTS-WQ10126MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10126MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8947MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ1902MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ1997MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ9113MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ6395MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ3248MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ10152MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ6220MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CR4098
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW